BEAM•benzinga•
Beam Therapeutics Announced Initial Safety And Efficacy Data From Its Phase 1/2 Trial Of BEAM-302, As Potential Treatment For Alpha-1 Antitrypsin Deficiency And For In Vivo Base Editing
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 10, 2025 by benzinga